States anxiously await news on cancer funding

And generic cancer drugs used around the world fail quality tests, resulting in ineffective or dangerous treatments

June 27, 2025 Check out STAT+

Sponsored By

STAT+ | States anxiously wait to find out if cancer tracking and prevention funding from CDC will be renewed Cancer registries face funding cuts as CDC decisions near. Experts warn cancer tracking and screening could suffer, emerging threats would remain hidden. By Isabella Cueto Generic cancer drugs used around the world fail quality tests, investigation shows Investigation finds too little or too much active ingredient in about a fifth of all chemotherapy samples; patients in 100 countries at risk By Paul Eccles, Andjela Milivojevic, and and Ramu Sapkota — TBIJ STAT+ | DeepMind launches AlphaGenome, aiming to predict gene regulation from DNA sequence DeepMind working on predicting how DNA encodes gene regulation with a new model called AlphaGenome, an early step toward possible therapeutic applications. By Katie Palmer Adobe STAT+ | Despite resumption of NIH grant reviews, research funding gap grew STAT analysis shows that the gap in NIH grant awards compared to past years has grown over the past two months, to $4.7 billion By Megan Molteni and J. Emory Parker

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser